Preserflo微分流器在开角青光眼手术中的两年疗效。

Q4 Medicine

Ceska a Slovenska Oftalmologie Pub Date : 2025-01-01 DOI:10.31348/2025/9

Veronika Fialová, Martin Váša, Pavel Rozsíval, Jitka Kalinová, Jan Studnička

{"title":"Preserflo微分流器在开角青光眼手术中的两年疗效。","authors":"Veronika Fialová, Martin Váša, Pavel Rozsíval, Jitka Kalinová, Jan Studnička","doi":"10.31348/2025/9","DOIUrl":null,"url":null,"abstract":"Aim: To evaluate the safety and efficacy outcomes of PRESERFLO™ MicroShunt implantation in patients with primary open-angle glaucoma.Material and methods: Retrospective data analysis of 19 eyes of 12 patients, comprising 5 females and 7 males. The patients underwent surgery between August 2020 and February 2022. The follow-up period was 24 months after surgery. During the follow-up period, intraocular pressure (IOP), the need to apply topical antiglaucoma medication and its spectrum, visual field status, optic nerve target findings and postoperative complications were recorded. The indication for PRESERFLO™ MicroShunt implantation was primary open angle glaucoma (POAG), poorly controlled with maximum tolerated medical therapy.Results: Average IOP was reduced from 19.05 ±5.58 mmHg preoperatively to 11.47 ±2.48 mmHg at 3 months postoperatively, 12.26 ±2.48 mmHg at 6 months postoperatively, 14.0 ±2.43 mmHg at 12 months postoperatively, 11.78 ±2.37 mmHg at 18 months postoperatively, and 12.73 ±2.51 mmHg at 24 months postoperatively (p.","PeriodicalId":39839,"journal":{"name":"Ceska a Slovenska Oftalmologie","volume":"81 Ahead of Print","pages":"1-8"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Two-year results of Preserflo Microshunt use in Open-angle Glaucoma Surgery.\",\"authors\":\"Veronika Fialová, Martin Váša, Pavel Rozsíval, Jitka Kalinová, Jan Studnička\",\"doi\":\"10.31348/2025/9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Aim: To evaluate the safety and efficacy outcomes of PRESERFLO™ MicroShunt implantation in patients with primary open-angle glaucoma.Material and methods: Retrospective data analysis of 19 eyes of 12 patients, comprising 5 females and 7 males. The patients underwent surgery between August 2020 and February 2022. The follow-up period was 24 months after surgery. During the follow-up period, intraocular pressure (IOP), the need to apply topical antiglaucoma medication and its spectrum, visual field status, optic nerve target findings and postoperative complications were recorded. The indication for PRESERFLO™ MicroShunt implantation was primary open angle glaucoma (POAG), poorly controlled with maximum tolerated medical therapy.Results: Average IOP was reduced from 19.05 ±5.58 mmHg preoperatively to 11.47 ±2.48 mmHg at 3 months postoperatively, 12.26 ±2.48 mmHg at 6 months postoperatively, 14.0 ±2.43 mmHg at 12 months postoperatively, 11.78 ±2.37 mmHg at 18 months postoperatively, and 12.73 ±2.51 mmHg at 24 months postoperatively (p.\",\"PeriodicalId\":39839,\"journal\":{\"name\":\"Ceska a Slovenska Oftalmologie\",\"volume\":\"81 Ahead of Print\",\"pages\":\"1-8\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ceska a Slovenska Oftalmologie\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.31348/2025/9\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ceska a Slovenska Oftalmologie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31348/2025/9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

目的：评价PRESERFLO™MicroShunt植入术治疗原发性开角型青光眼的安全性和有效性。材料与方法：回顾性分析12例患者19眼的资料，其中女5例，男7例。这些患者在2020年8月至2022年2月期间接受了手术。术后随访24个月。随访期间记录眼内压（IOP）、外用抗青光眼药物的需求及其谱、视野状况、视神经靶点表现及术后并发症。PRESERFLO™MicroShunt植入术的适应症是原发性开角型青光眼（POAG），在最大耐受药物治疗下控制不良。结果：平均IOP由术前19.05±5.58 mmHg降至术后3个月11.47±2.48 mmHg，术后6个月12.26±2.48 mmHg，术后12个月14.0±2.43 mmHg，术后18个月11.78±2.37 mmHg，术后24个月12.73±2.51 mmHg （p < 0.05）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Two-year results of Preserflo Microshunt use in Open-angle Glaucoma Surgery.

Aim: To evaluate the safety and efficacy outcomes of PRESERFLO™ MicroShunt implantation in patients with primary open-angle glaucoma.

Material and methods: Retrospective data analysis of 19 eyes of 12 patients, comprising 5 females and 7 males. The patients underwent surgery between August 2020 and February 2022. The follow-up period was 24 months after surgery. During the follow-up period, intraocular pressure (IOP), the need to apply topical antiglaucoma medication and its spectrum, visual field status, optic nerve target findings and postoperative complications were recorded. The indication for PRESERFLO™ MicroShunt implantation was primary open angle glaucoma (POAG), poorly controlled with maximum tolerated medical therapy.

Results: Average IOP was reduced from 19.05 ±5.58 mmHg preoperatively to 11.47 ±2.48 mmHg at 3 months postoperatively, 12.26 ±2.48 mmHg at 6 months postoperatively, 14.0 ±2.43 mmHg at 12 months postoperatively, 11.78 ±2.37 mmHg at 18 months postoperatively, and 12.73 ±2.51 mmHg at 24 months postoperatively (p.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Ceska a Slovenska Oftalmologie Medicine-Ophthalmology

CiteScore

0.80

自引率

0.00%

发文量

期刊介绍： - Redakce přijímá pouze práce vyhovující po odborné stránce, které jsou na odpovídající profesionální a formální úrovni. - Uveřejněná práce se stává majetkem časopisu, přetisknout její část nebo obrázek lze jen s citací původu. - Rukopis zasílejte v originále a dobře čitelné kopii (je nutná také kopie tabulek, legend, podle možnosti i obrázků). - Listy číslujte v pravém horním rohu a spojujte svorkou, nesešívejte. Přijímáme práce psané na jedné straně kvalitního bílého nelesklého papíru formátu A4 (neprůklepový) na psacím stroji nebo počítači s obvyklými typy.